Literature DB >> 16443920

Exenatide (exendin-4)-induced pancreatitis: a case report.

Paul S Denker, Paul E Dimarco.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16443920     DOI： 10.2337/diacare.29.02.06.dc05-2043

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  40 in total

1.  Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents.

Authors:  Krystyna Tatarkiewicz; Pamela A Smith; Emmanuel J Sablan; Clara J Polizzi; Donald E Aumann; Christiane Villescaz; Diane M Hargrove; Bronislava R Gedulin; Melissa G W Lu; Lisa Adams; Tina Whisenant; Denis Roy; David G Parkes
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-10-05       Impact factor: 4.310

2.  Balancing benefits and risks in patients receiving incretin-based therapies: focus on cardiovascular and pancreatic side effects.

Authors:  Martin Haluzík; Miloš Mráz; Štěpán Svačina
Journal:  Drug Saf       Date:  2014-12       Impact factor: 5.606

3.  Drug-induced acute pancreatitis.

Authors:  Tracie Kaurich
Journal:  Proc (Bayl Univ Med Cent)       Date:  2008-01

4.  Incretin-based therapies: facing the realities of benefits versus side effects.

Authors:  Harold E Lebovitz
Journal:  Diabetes Technol Ther       Date:  2013-10-10       Impact factor: 6.118

Review 5.  Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.

Authors:  Chris de Graaf; Dan Donnelly; Denise Wootten; Jesper Lau; Patrick M Sexton; Laurence J Miller; Jung-Mo Ahn; Jiayu Liao; Madeleine M Fletcher; Dehua Yang; Alastair J H Brown; Caihong Zhou; Jiejie Deng; Ming-Wei Wang
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

6.  Multivalent activation of GLP-1 and sulfonylurea receptors modulates β-cell second-messenger signaling and insulin secretion.

Authors:  Nathaniel J Hart; Craig Weber; Klearchos K Papas; Sean W Limesand; Josef Vagner; Ronald M Lynch
Journal:  Am J Physiol Cell Physiol       Date:  2018-11-07       Impact factor: 4.249

Review 7.  Obesity treatment: novel peripheral targets.

Authors:  Benjamin C T Field; Owais B Chaudhri; Stephen R Bloom
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

8.  Collateral damage: the conundrum of drug safety.

Authors:  E A M Gale
Journal:  Diabetologia       Date:  2009-10       Impact factor: 10.122

Review 9.  Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies.

Authors:  Megan C Chapter; Caitlin M White; Angela DeRidder; Wayne Chadwick; Bronwen Martin; Stuart Maudsley
Journal:  Pharmacol Ther       Date:  2009-08-15       Impact factor: 12.310

10.  Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population.

Authors:  John A Romley; Dana P Goldman; Matthew Solomon; Daniel McFadden; Anne L Peters
Journal:  Diabetes Technol Ther       Date:  2012-07-30       Impact factor: 6.118
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.